Observing MrgD levels in patients with pulmonary hypertension

Circulating MrgD Change in Patients With Pulmonary Hypertension

This study looks at the levels of a protein called MrgD in people with pulmonary hypertension compared to those without the condition to better understand its role and how it might help with treatment.

Quick facts

• Study type: Observational
• Enrollment: 90 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Qilu Hospital of Shandong University (Academic / other)
• Locations: 1 site (Jinan, Shandong)
• Trial ID: NCT06365372 on ClinicalTrials.gov

What this trial studies

This observational study aims to measure and compare the levels of circulating MrgD in patients diagnosed with pulmonary hypertension against those without the condition. It involves right heart catheterization to confirm pulmonary artery pressure and utilizes Western blot techniques for analysis. The study seeks to enhance understanding of the role of MrgD in pulmonary hypertension and its potential implications for treatment.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with confirmed pulmonary hypertension as indicated by elevated mean pulmonary artery pressure.

Not a fit: Patients with conditions such as renal or liver insufficiency, malignant tumors, or those who are pregnant may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the biological mechanisms of pulmonary hypertension and identify potential biomarkers for diagnosis or treatment.

How similar studies have performed: While this approach is observational and may not have been extensively tested, similar studies investigating biomarkers in pulmonary hypertension have shown promise.

Eligibility criteria

Inclusion criteria for patients with pulmonary hypertension：

1. Male or female aged ≥18 years
2. Right heart catheterisation to check the mean pulmonary artery pressure (mPAP) ≥25mmHg
3. The patient is willing and able to provide written informed consent.

Exclusion criteria for patients with pulmonary hypertension：

1. Age less than 18 years old
2. Mean pulmonary artery pressure (mPAP) \<25mmHg
3. Unable to provide informed written consent for participation in the study
4. Renal insufficiency
5. Liver insufficiency
6. Malignant tumor
7. Active infection
8. Pregnancy

Inclusion criteria for control subjects：

1. Male or female aged ≥18 years
2. No evidence of pulmonary hypertension on echocardiography or mean pulmonary artery pressure (mPAP) \< 25 mmHg on right heart catheterization, and no evidence of clinically relevant heart disease
3. No evidence of clinically relevant pulmonary disease

Exclusion criteria for control subjects：

1. Age less than 18 years old
2. Mean pulmonary artery pressure (mPAP) ≥25mmHg
3. Unable to provide informed written consent for participation in the study
4. Symptoms of heart failure or clinically relevant lung disease
5. Renal insufficiency
6. Liver insufficiency
7. Malignant tumor
8. Active infection
9. Pregnancy

Where this trial is running

Jinan, Shandong

• Qilu Hospital of Shandong University — Jinan, Shandong, China (Recruiting)

Study contacts

• Study coordinator: Panpan Hao, MD

Conditions Pulmonary Hypertension